SCHEMBL16468397

SCHEMBL16468397

O=C(O)C1CC(Oc2ccc(Br)cc2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
EPHX2 P34913 2/20 0.43
LDHA P00338 1/20 0.42
LMNA P02545 2/20 0.41
SENP8 Q96LD8 2/20 0.41
SENP6 Q9GZR1 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CASP3 P42574 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
PARP10 Q53GL7 1/20 0.38
KDM4E B2RXH2 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
P2RX3 P56373 1/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16468399 1.00 POLB (0.46) POLBEPHX2LDHALMNASENP8
SCHEMBL22463663 0.85 PARP10 (0.46) POLBEPHX2TDP1PARP10SMN1; SMN2
SCHEMBL22578255 0.85 PARP10 (0.46) POLBEPHX2TDP1PARP10SMN1; SMN2
SCHEMBL22578254 0.85 PARP10 (0.46) POLBEPHX2TDP1PARP10SMN1; SMN2
SCHEMBL25184897 0.84 POLB (0.51) POLBEPHX2LDHAPARP10
SCHEMBL25184896 0.84 POLB (0.51) POLBEPHX2LDHAPARP10
SCHEMBL795203 0.83 SLC6A4 (0.52) EPHX2LMNASENP8SENP6ALDH1A1
SCHEMBL31381195 0.82 SLC6A4 (0.53) EPHX2LMNASENP8SENP6ALDH1A1
SCHEMBL31381274 0.82 SLC6A4 (0.53) EPHX2LMNASENP8SENP6ALDH1A1
SCHEMBL19282784 0.81 SMN1; SMN2 (0.45) EPHX2LMNAALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9751887-B2 Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-09-05 US disclosed
EP-2857404-B1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS DAIICHI SANKYO CO LTD (JP) 2017-08-23 EP disclosed
US-20160046639-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-02-18 US disclosed
US-9187489-B2 Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-11-17 US disclosed
EP-2857404-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR Daiichi Sankyo Co., Ltd. (JP) 2015-04-08 EP disclosed
US-20150051190-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051190-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS ROS1, JAK1, ERBB2 POLB 3415/4885EPHX2 4503/4885LDHA 2906/4885
US-20160046639-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS ROS1, JAK1, ERBB2 POLB 3415/4885EPHX2 4503/4885LDHA 2906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.